맨카인드(MNKD)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.57 (-0.28%), 시가총액 $1.00B, 52주 최저~최고 $2.28 ~ $6.21.
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with intersti
맨카인드의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
맨카인드의 현재 주가는 $3.57 (-0.28%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
맨카인드의 시가총액은 약 $1.00B입니다.
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious u